Elwood & Goetz Wealth Advisory Group LLC Sells 21 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Elwood & Goetz Wealth Advisory Group LLC cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 471 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. Elwood & Goetz Wealth Advisory Group LLC’s holdings in Regeneron Pharmaceuticals were worth $336,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Howard Capital Management Inc. raised its holdings in Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Howard Capital Management Inc. now owns 3,102 shares of the biopharmaceutical company’s stock worth $2,210,000 after buying an additional 89 shares during the last quarter. Sigma Planning Corp raised its holdings in Regeneron Pharmaceuticals by 91.2% during the fourth quarter. Sigma Planning Corp now owns 782 shares of the biopharmaceutical company’s stock worth $557,000 after buying an additional 373 shares during the last quarter. Callan Capital LLC raised its holdings in Regeneron Pharmaceuticals by 13.5% during the fourth quarter. Callan Capital LLC now owns 412 shares of the biopharmaceutical company’s stock worth $293,000 after buying an additional 49 shares during the last quarter. Drum Hill Capital LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $214,000. Finally, Centricity Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $67,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $700.33 on Friday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a 50-day simple moving average of $699.40 and a 200 day simple moving average of $882.47. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $76.56 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $11.86 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Analyst Ratings Changes

REGN has been the topic of several research reports. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Oppenheimer lowered their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.